| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy (NCT06782854) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-02-21 |
| TOtal Skin Electron Beam Therapy (Low-dose) for Tumor Clone Eradication in Early-stage Mycosis Fungoides (NCT05205902) | Assistance Publique - Hôpitaux de Paris | 2022-02-01 |
| A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL (NCT05138458) | Myeloid Therapeutics | 2021-12-15 |
| Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides (NCT05303480) | Centre for Human Drug Research, Netherlands | 2021-12-07 |
| A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat (NCT04955340) | 4SC AG | 2021-10-12 |
| Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome (NCT04960618) | Memorial Sloan Kettering Cancer Center | 2021-10-01 |
| Photopheresis in Early-stage Mycosis Fungoides (NCT05680558) | Columbia University | 2021-05-08 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides (NCT04676087) | Emory University | 2021-04-21 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment (NCT04541017) | National Cancer Institute (NCI) | 2021-04-06 |
| Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome. (NCT04904146) | Lund University Hospital | 2021-04-02 |
| Effectiveness of Imiquimod Topical Cream in Early Stage Cutaneous T-cell Lymphoma (NCT02301494) | Rochester General Hospital | 2020-04-01 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome (NCT04256018) | Stanford University | 2020-03-30 |
| Phase I Study of Recombinant Human IL-15 (rhIL-15) and Mogamulizumab for People With Refractory or Relapsed Adult T-Cell Leukemia and Mycosis Fungoides/Sezary Syndrome (NCT04185220) | National Cancer Institute (NCI) | 2020-02-26 |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides (NCT03695471) | Mayo Clinic | 2020-02-04 |
| Biodynamic Imaging Utility in Predicting Response to Gemcitabine Chemotherapy in Mycosis Fungoides (NCT03789864) | Indiana University | 2019-10-07 |
| Interleukin-15 (IL-5) in Combination With Avelumab (Bavencio) in Relapsed/Refractory Mature T-cell Malignancies (NCT03905135) | National Cancer Institute (NCI) | 2019-06-07 |
| Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL (NCT03602157) | UNC Lineberger Comprehensive Cancer Center | 2018-10-29 |
| Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides (NCT03288818) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-08-01 |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients (NCT03587844) | Memorial Sloan Kettering Cancer Center | 2018-07-03 |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma (NCT02341209) | Rochester General Hospital | 2018-02-06 |
| Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides (NCT03398161) | M.D. Anderson Cancer Center | 2018-01-06 |
| Mechlorethamine Induced Contact Dermatitis Avoidance Study (NCT03380026) | Rochester Skin Lymphoma Medical Group, PLLC | 2017-12-13 |
| Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL (NCT02811783) | Elorac, Inc. | 2017-01-01 |
| Cell-free Circulating DNA in Primary Cutaneous Lymphomas (NCT02883517) | University Hospital, Bordeaux | 2016-11-22 |
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) (NCT02953301) | 4SC AG | 2016-11-01 |
| ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome (NCT02848274) | Stanford University | 2016-10-01 |
| Low Dose Total Skin Electron Beam Treatment (TSEBT) Followed by Maintenance Valchlor for Patients With Mycosis Fungoides (NCT02881749) | Thomas Jefferson University | 2016-09-01 |
| Trial of Intratumoral Injections of TTI-621 in Subjects With Relapsed and Refractory Solid Tumors and Mycosis Fungoides (NCT02890368) | Pfizer | 2016-09-01 |
| Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma (NCT02652715) | Mayo Clinic | 2016-01-19 |
| NM-IL-12 in Cutaneous T-Cell Lymphoma (CTCL) Undergoing Total Skin Electron Beam Therapy (TSEBT) (NCT02542124) | Neumedicines Inc. | 2015-12-01 |
| Vietnam Cryptococcal Retention in Care Study - Version 2.1 (NCT03267407) | National Hospital for Tropical Diseases, Hanoi, Vietnam | 2015-08-14 |
| Clinical Study Assessing Outcomes, Adverse Events, Treatment Patterns, and Quality of Life in Patients Diagnosed With Mycosis Fungoides Cutaneous T-cell Lymphoma (NCT02296164) | Helsinn Therapeutics (U.S.), Inc | 2014-11-12 |
| Comparison of Methotrexate Versus Interferon-alfa 2b in Patients With Primary Cutaneous T-cell Lymphomas (NCT02323659) | Polish Lymphoma Research Group | 2014-06-01 |
| Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma (NCT01590732) | M.D. Anderson Cancer Center | 2012-10-29 |
| A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study) (NCT01578499) | Millennium Pharmaceuticals, Inc. | 2012-06-11 |
| SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP) (NCT01352520) | M.D. Anderson Cancer Center | 2011-06-01 |
| Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing (NCT01556828) | Stanford University | 2011-06-01 |
| Brentuximab Vedotin (SGN-35) in Patients With Mycosis Fungoides With Variable CD30 Expression Level (NCT01396070) | Youn Kim | 2011-05-01 |
| A-dmDT390-bisFv(UCHT1) Immunotoxin Therapy for Patients With Cutaneous T-Cell Lymphoma (CTCL) (NCT00611208) | Virogen Biotechnology Inc. | 2008-01-01 |
| An Open Label Study to Evaluate the Safety and Efficacy of Mechlorethamine(MCH) 0.04% Formulation in Mycosis Fungoides (NCT00535470) | Yaupon Therapeutics | 2007-07-01 |
| Topical Romidepsin to Treat Early-Stage Cutaneous T-Cell Lymphoma (NCT01445340) | National Cancer Institute (NCI) | 2007-04-21 |
| T Cell Repertoire Analysis of Immune Mediated Skin Diseases (NCT00368784) | University of California, Davis | 2007-01-01 |
| Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides (NCT00168064) | Yaupon Therapeutics | 2006-05-01 |
| Effect of Denileukin Diftitox on Immune System in CTCL Patients (NCT00254332) | University of Pittsburgh | 2005-11-01 |
| Study of Alemtuzumab to Treat Advanced Mycosis Fungoides/Sezary Syndrome (NCT00157274) | Latin American Cooperative Onco-Haematology Group - Peru | 2005-07-01 |
| Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome (NCT00127881) | Emergent Product Development Seattle LLC | 2005-07-01 |
| Combination Drug Study of Bexarotene and Rosiglitazone to Treat CTCL (NCT00178841) | Vanderbilt University | 2005-06-01 |
| Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-cell Lymphoma (0683-001) (NCT00091559) | Merck Sharp & Dohme LLC | 2005-02-03 |
| Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research (NCT00177268) | University of Pittsburgh | 2004-10-01 |
| CPG 7909 + Local Radiotherapy in Recurrent Low-Grade Lymphomas (NCT00185965) | Ronald Levy | 2004-07-01 |
| Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A (NCT00221039) | M.D. Anderson Cancer Center | 2004-04-02 |
| Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome (NCT00047060) | National Heart, Lung, and Blood Institute (NHLBI) | 2002-07-30 |
| In Vitro Evaluation of Immune Responses in Cutaneous T-Cell Lymphoma (CTCL) (NCT00177190) | University of Pittsburgh | 2002-06-01 |
| Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides (NCT00496743) | Bispebjerg Hospital | 2002-01-01 |
| Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions (NCT00129415) | University of Michigan | 2000-08-01 |
| Study of ONTAK (Denileukin Diftitox) in Cutaneous T-Cell Lymphoma (CTCL) Patients (NCT00050999) | Eisai Inc. | 1995-06-01 |
| Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies (NCT00038376) | M.D. Anderson Cancer Center | 1990-05-08 |